Blood

Worldwide Patient Blood Management Industry to 2025 - Impact of COVID-19 with Ansoff Analysis - ResearchAndMarkets.com

Friday, March 5, 2021 - 5:29pm

Based on Product, the Global Patient Blood Management Market is segmented into instruments, accessories, reagents & kits, and software.

Key Points: 
  • Based on Product, the Global Patient Blood Management Market is segmented into instruments, accessories, reagents & kits, and software.
  • Based on End-Users, The Blood Bank Segment is the fastest-growing end-user segment in the patient blood management market.
  • Based on Components, the Patient Blood Management Market is segmented into whole blood & red blood cells, and Plasma.
  • The Whole Blood & Red Blood Cells contributes to a major share of the market due to the increasing number of blood donors across the globe.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Friday, March 5, 2021 - 4:30pm

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • Glancy Prongay & Murray LLP, Los Angeles

Fidelis Specialty Pharmacy Selects Citus Health to Enable Real-Time Virtual Patient Communications and Faster Collection of Key Patient Data

Thursday, March 4, 2021 - 3:00pm

Through its URAC accredited specialty pharmacy, Fidelis Specialty Pharmacy dispenses medications to treat hemophilia and bleeding disorder complications that arise from factor deficiencies.

Key Points: 
  • Through its URAC accredited specialty pharmacy, Fidelis Specialty Pharmacy dispenses medications to treat hemophilia and bleeding disorder complications that arise from factor deficiencies.
  • Patients who receive routine prophylactic infusions often benefit from learning how to self-infuse, which the Citus Health platform will help enable with on-demand patient education tools.
  • As an exclusive provider to patients with bleeding disorders, therapy non-adherence is a critical issue for Fidelis and a driving force behind selecting the Citus Health platform.
  • Fidelis Specialty Pharmacy is a Latino-owned specialty pharmacy servicing the bleeding disorders community.

Worldwide Patient Blood Management Industry to 2025 - Growing Awareness Regarding the Safety of Donated Blood Presents Opportunities - ResearchAndMarkets.com

Thursday, March 4, 2021 - 1:28pm

Blood Management is carried out by doctors for patients that possess the risk of blood loss at the time of surgical intervention.

Key Points: 
  • Blood Management is carried out by doctors for patients that possess the risk of blood loss at the time of surgical intervention.
  • The accelerating demand for blood banks across the globe and the prevailing ratio of blood diseases such as anemia, leukemia has catered the patient blood management.
  • The rising number of accidental incidences, trauma cases, and surgical procedures fuels the growth of the global patient blood management market.
  • The high cost associated with the automated systems is expected to hinder the growth of the Global Patient Blood Management Market.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Thursday, March 4, 2021 - 8:00am

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

Enzyre announces strategic partnership with Takeda to accelerate development of pioneering diagnostic technology platform for hemophilia patients

Thursday, March 4, 2021 - 8:00am

Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.

Key Points: 
  • Takeda confirmed the partnership by investing in Enzyre and joining its supervisory board.
  • The Hemophilia Enzycard, the first product using Enzyre's proprietary Enzypad platform technology, can be used to determine the coagulation status of patients with hemophilia, a rare genetic disorder that affects an estimated 400,000 people worldwide.
  • [1] Those with hemophilia lack sufficient blood-clotting proteins, for example factor VIII (FVIII), causing them to bleed for a longer time after an injury compared to people without hemophilia.
  • Enzycard will enable patients to test in a home setting, immediately transferring coagulation status results to the patient's treating physician through a mobile phone app.

New Study Contributes to Evidence for Potential Association between Blood Group A and Risk of COVID-19 Infection

Wednesday, March 3, 2021 - 8:11pm

The team assessed synthetic blood group antigens on respiratory and red blood cells found in blood group A, B, and O individuals, and analyzed how the SARS-CoV-2 RBD interacted with each unique blood type.

Key Points: 
  • The team assessed synthetic blood group antigens on respiratory and red blood cells found in blood group A, B, and O individuals, and analyzed how the SARS-CoV-2 RBD interacted with each unique blood type.
  • They discovered that the RBD had a strong preference for binding to blood group A found on respiratory cells.
  • It did not display a preference for blood group A red blood cells, or other blood groups found on respiratory or red cells.
  • The capacity of the RBD to preferentially recognize and attach to the blood type A antigen found in the lungs of blood type A individuals may provide insight into the potential link between blood group A and COVID-19 infection.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Wednesday, March 3, 2021 - 4:30pm

Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .

Key Points: 
  • Investors suffering losses on their Immunovant investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com .
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Monday, March 1, 2021 - 5:00pm

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
  • On September 29, 2019, HSAC entered into an agreement with Immunovant Sciences Ltd. (Legacy Immunovant) to effect a merger between the two entities (the Merger).
  • The Company has also completed initiation of Phase II clinical trials of IMVT-1401 for the treatment of warm autoimmune hemolytic anemia (WAIHA).
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

Global Single Blood Drop Analysis Market Expected to Reach USD 43,921.5 Million by 2027 With A CAGR Of 11.5% | Growth Market Reports

Friday, February 26, 2021 - 2:30pm

The global single blood drop analysis market is fragmented based on type, applications, end-users.

Key Points: 
  • The global single blood drop analysis market is fragmented based on type, applications, end-users.
  • Based on type,the global single blood drop analysis market is divided into blood collection, blood analyzers, and consumables.
  • Based on applications,the global single blood drop analysis market is divided into cancer, diabetics, cardiovascular, viral/bacterial infection, fertility, and allergy.
  • The diabetics segment is anticipated to hold a significant share of the single blood drop analysis market during the forecast period.